Package leaflet: Information for the user
ZALTRAP 25 mg/ml concentration for solution for infusion aflibercept
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
•Keep this leaflet. You may need to read it again, or provide it to future healthcare providers.
•If you have any further questions, ask your doctor, pharmacist or nurse.
•If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1.What ZALTRAP is and what it is used for
2.What you need to know before you are given ZALTRAP
3.How ZALTRAP is given
4.Possible side effects
5.How to store ZALTRAP
6.Contents of the pack and other information
1.What ZALTRAP is and what it is used for
What ZALTRAP is and how it works
ZALTRAP contains the active substance aflibercept, a protein that works by blocking the growth of new blood vessels within the tumour. The tumour needs nutrients and oxygen from blood in order to grow. By blocking the growth of blood vessels, ZALTRAP helps to stop or slow down the growth of the tumour.
What ZALTRAP is used for
ZALTRAP is a medicine used to treat advanced cancers of the colon or rectum (parts of the large intestine) in adults. It will be given with other medicines called ‘chemotherapy’, including
2. What you need to know before you are given ZALTRAP
Do not use ZALTRAP:
•if you are allergic to aflibercept or any of the other ingredients of this medicine (listed in section 6).
•in your eye, since it may severely damage it.
Please also read the package leaflets for the other medicines (‘chemotherapy’) that are part of your treatment, to see if they are suitable for you. If you are unsure, ask your doctor, pharmacist or nurse if there are any reasons why you cannot use these medicines.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before you are given ZALTRAP and during your treatment if:
•you have any bleeding problems or if you notice any bleeding after treatment (see section 4) or if you feel extreme tiredness, weakness, dizziness, or have changes in the colour of your stool. If the
bleeding is severe, your doctor will stop your treatment with ZALTRAP. This is because ZALTRAP may increase the risk of bleeding.
•you have any problems with your mouth or teeth such as poor dental health, gum disease, or a planned tooth extraction and especially if you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders). A side effect called osteonecrosis (bone damage in the jaw) has been reported in cancer patients treated with ZALTRAP. You may be advised to have a dental
•you have illnesses where your gut is inflamed, such as an infected section of the bowel wall (also called ‘diverticulitis’), stomach ulcers or colitis. This is because ZALTRAP may increase the risk of developing holes in the gut wall. If this should happen to you, your doctor will stop your treatment with ZALTRAP.
•you have had any abnormal
•you have high blood pressure. Zaltrap may increase blood pressure (see section 4) and your doctor will need to monitor your blood pressure and may adjust your blood pressure medicines or your dose of ZALTRAP. It is therefore also important to tell your doctor, pharmacist or nurse if you have other heart problems since high blood pressure could make these worse.
•you experience shortness of breath (dyspnea) when you exert yourself or when you lie down, excessive tiredness or leg swelling which may be signs of heart failure.
•you experience signs of a blood clot (see section 4). The signs of a blood clot may vary depending on where it appears (e.g. lungs, leg, heart or brain) but may include symptoms such as chest pain, coughing, being short of breath or having difficulty breathing. Other signs may include swelling in one or both legs, pain or tenderness in one or both legs, discolouration and warmth of the skin on the affected leg or visible veins. It may also present itself as a sudden numb or weak feeling in the face, arms, or legs. Other signs include feeling confused, problems with sight, walking, coordination or balance, problems in saying words or slurring of speech. If you experience any of these symptoms, talk to your doctor immediatley since your doctor may want to treat your symptoms and stop your treatment with ZALTRAP.
•you have kidney problems (protein in the urine), since your doctor will monitor your kidney function and may need to adjust your dose of ZALTRAP.
•your number of white blood cells is too low. Zaltrap may reduce the number of white cells in your blood and your doctor will monitor your white blood cell count and may give you additional medicines to increase it. If your white blood cells are low, your doctor may need to delay your treatment.
•you have severe or
•you have ever had any allergies - serious allergic reactions can happen during treatment with ZALTRAP (see section 4). Your doctor may need to treat the allergic reaction or stop your treatment with ZALTRAP.
•you have had a tooth removed or any form of surgery in the last 4 weeks, or you are going to have an operation or a dental or medical procedure, or you have a wound after surgery that has not healed. Your doctor will temporarily stop the treatment before and after surgery.
•you experience fits (seizures). If you experience changes in your vision or confusion, your doctor may stop your treatment with ZALTRAP.
•you are 65 years of age or older and experience diarrhoea, dizziness, weakness, weight loss, or severe loss of body fluids (called ‘dehydration’). Your doctor should monitor you carefully.
•your level of everyday activities is limited or worsens on treatment. Your doctor should monitor you carefully.
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given ZALTRAP and during your treatment.
During treatment, your doctor will perform a number of tests to monitor the function of your body and how the medicine is working. Tests may include blood and urine tests,
ZALTRAP is given by a drip (infusion) into one of your veins
Children and adolescents
Do not give this medicine to children or adolescents under the age of 18 years because the safety and benefit of using ZALTRAP in children and adolescents have not been shown.
Other medicines and ZALTRAP
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This may include medicines obtained without a prescription or herbal medicines.
You should not use ZALTRAP during pregnancy unless you and your doctor decide that the benefit for you is greater than any possible risk to you or your unborn baby.
If you are a woman that could become pregnant you should use effective contraception (see “Contraception” section below for details on male and female contraception). This medicine may harm your unborn baby since it may stop new blood vessels from forming.
Talk to your doctor before being given this medicine if you are
ZALTRAP may affect male and female fertility. Talk to your doctor for advice if you plan to have or father a child.
Men and women who can father or have children should use effective contraception:
•during treatment with ZALTRAP and
•for at least 6 months after the last dose of treatment.
Driving and using machines
You may have side effects that affect your sight, concentration or ability to react. If this happens, do not drive or use any tools or machines.
- Eylea - aflibercept
Prescription drugs listed. Substance: "Aflibercept"
3.How ZALTRAP is given
ZALTRAP will be given to you by a doctor or a nurse that is experienced in the use of ‘chemotherapy’. It is given by a drip (infusion) into one of your veins
The medicine must be diluted before it is given. Practical information for handling and administration of ZALTRAP for doctors, nurses and pharmacists when using this medicine, is provided with this leaflet.
How much and how often you will receive treatment
•The drip (infusion) lasts for about 1 hour.
•You will usually be given an infusion once every 2 weeks.
•The recommended dose is 4 mg for each kilogram of your body weight. Your doctor will decide the correct dose for you.
•Your doctor will decide how often you will be given the medicine and if you need a change in the dose.
ZALTRAP will be given with other chemotherapy medicines including
Treatment will continue as long as your doctor thinks the treatment is of benefit to you, and the side effects are acceptable.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4.Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The side effects listed below were seen when ZALTRAP was given together with chemotherapy.
Serious side effects
Talk to your doctor straight away, if you notice any of the following serious side effects - you may need urgent medical treatment:
•Bleeding: Very common (may affect more than 1 in 10 people) - this includes bleeding from the nose, but may also include severe bleeding in your gut and other parts of the body, which may lead to death. Signs may include feeling very tired, weak, and/or dizzy, or having changes in the colour of your stool.
•Pain in the mouth, teeth and/or jaw, swelling or
(may affect up to 1 in 100 people) - These symptoms could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms while being treated with ZALTRAP or after stopping treatment.
•Holes in the gut (also called
•Connections or passageways inside the body between internal organs and skin or other tissues (also called ‘fistula’): Common (may affect up to 1 in 10 people) - these abnormal
•High blood pressure (also called ‘hypertension’): Very common (may affect more than 1 in 10 people) - this may develop or get worse. If blood pressure is not controlled, it may cause stroke, heart and kidney problems. Your doctor should check your blood pressure throughout your treatment.
•Heart failure (also called cardiac failure); Uncommon (may affect up to 1 in 100 people) – Signs may include shortness of breath when you lie down or when you exert yourself, excessive tiredness or leg swelling.
•Blocking of the arteries by a blood clot (also called ‘arterial
•Blocking of the veins by a blood clot (also called ‘venous
•Protein in the urine (also called ‘proteinuria’): Very common (may affect more than 1 in 10 people) – this is very commonly seen in tests. This may include swelling of the feet or whole body and may be related to kidney disease.
•Low white blood cell count (also called ‘neutropenia’): Very common (may affect more than 1 in 10 people) - this can cause serious infections. Your doctor will do blood tests regularly to check your white blood cell counts throughout your treatment. They may also prescribe a medicine called
•Diarrhoea and dehydration: Very common (may affect more than 1 in 10 people) for diarrhoea and Common (may affect up to 1 in 10 people) for dehydration - severe diarrhoea and being sick (vomiting) can cause you to lose too much body fluid (called ‘dehydration’) and body salts (electrolytes). Signs may include dizziness especially when going from sitting to standing. You may need to go to the hospital for treatment. Your doctor may give you medicines to stop or treat diarrhoea and being sick (vomiting).
•Allergic reactions: Common (may affect up to 1 in 10 people) - these may happen within a few minutes after your infusion. Signs of allergic reaction may include rash or itching, skin redness, feeling dizzy or faint, being short of breath, tight chest or throat, or swelling of the face. Tell your doctor or nurse straight away if you have any of these signs during or soon after an infusion of ZALTRAP.
•Wounds which heal slowly or not at all: Uncommon (may affect up to 1 in 100 people) - this is when a scar has trouble healing or staying closed, or if a healed wound
•A side effect which affects your nervous system (called ‘posterior reversible encephalopathy syndrome’ or PRES): Uncommon (may affect up to 1 in 100 people) - signs may include headache, sight changes, feeling confused or fits with or without high blood pressure.
Talk to your doctor straight away, if you notice any of the side effects above.
Other side effects include:
Very common (may affect more than 1 in 10 people)
•drop in the number of white blood cells (leucopenia)
•drop in the number of certain cells in the blood that help it to clot (thrombocytopenia)
•change of the voice, e.g. developing a hoarse voice
•difficulty when breathing
•painful sores in the mouth
•swelling and numbness of the hands and feet that happens with chemotherapy (called
•feeling tired or weak
•kidney problem with an increase in creatinine (a marker of kidney function)
•liver problem with an increase in liver enzymes.
Common (may affect up to 1 in 10 people)
•urinary tract infection
•inflammation inside the nose and upper part of the throat
•pain in the mouth or throat
•haemorrhoids, bleeding or pain in the back passage
•inflammation inside the mouth
•changes in the colour of the skin.
Uncommon (may affect up to 1 in 100 people)
•an increase in protein in the urine, an increase in cholesterol in the blood, and swelling from excess fluid (oedema) (also called ‘nephrotic syndrome’)
•blood clot in very small blood vessels (also called ‘thrombotic microangiopathy’).
- Irbesartan hydrochlorothiazide zentiva (irbesartan hydrochlorothiazide winthrop) - sanofi-aventis groupe
- Praluent - sanofi-aventis groupe
- Jevtana - sanofi-aventis groupe
- Karvea - Sanofi-aventis groupe
- Karvezide - Sanofi-aventis groupe
- Aubagio - Sanofi-aventis Groupe
Prescription drugs listed. Manufacturer: "Sanofi-Aventis Groupe"
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5.How to store ZALTRAP
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton and on the label of the vial after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C - 8°C).
Store in the original package in order to protect from light.
Information about storage and the time to use ZALTRAP, after it has been diluted and is ready to use, is described in the ‘Practical information for healthcare professionals on preparation and handling of ZALTRAP 25 mg/ml concentrate for solution for infusion’ at the end of this leaflet.
Do not use ZALTRAP if you notice particles or discolouration of the medicine in the vial or infusion bag.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What ZALTRAP contains
•The active substance is aflibercept. One ml of concentrate contains 25 mg aflibercept. One 4 ml vial of concentrate contains 100 mg aflibercept. One 8 ml vial of concentrate contains 200 mg aflibercept.
•The other ingredients are: sucrose, sodium chloride, sodium citrate dihydrate, citric acid monohydrate, polysorbate 20, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, sodium hydroxide and/or hydrochloric acid and water for injections.
What ZALTRAP looks like and contents of the pack
ZALTRAP is a concentrate for solution for infusion (sterile concentrate). The concentrate is a clear, colourless to pale yellow solution.
•4 ml of concentrate in a 5 ml clear borosilicate glass vial (type I), sealed by a flanged stopper with
•8 ml of concentrate in a 10 ml clear borosilicate glass vial (type I), sealed by a flanged stopper with
Not all pack sizes may be marketed.
Marketing Authorisation Holder
54, rue La Boétie 75008 Paris France
65926 Frankfurt am Main Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Tél/Tel: +32 (0)2 710 54 00
Tel: +370 5 2755224
Тел.: +359 (0)2 970 53 00
Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien)
Tel: +420 233 086 111
Tel.: +36 1 505 0050
Tlf: +45 45 16 70 00
Tel: +356 21493022
Tel: +49 (0)180 2 222010
Tel: +31 (0)182 557 755
Tel: +372 627 34 88
Tlf: +47 67 10 71 00
Τηλ: +30 210 900 16 00
Tel: +43 1 80 185 – 0
Tel: +34 93 485 94 00
Tel.: +48 22 280 00 00
Sanofi - Produtos Farmacêuticos, Lda.
Tél: 0 800 222 555
Tel: +351 21 35 89 400
Appel depuis l’étranger : +33 1 57 63 23 23
Sanofi Romania SRL
Tel: +385 1 600 34 00
Tel: +40 (0) 21 317 31 36
Tel: +353 (0) 1 403 56 00
Tel: +386 1 560 48 00
Sími: +354 535 7000
Tel: +421 2 33 100 100
Tel: 800 536389
Puh/Tel: +358 (0) 201 200 300
Τηλ: +357 22 871600
Tel: +46 (0)8 634 50 00
Tel: +371 67 33 24 51
Tel: +44 (0) 845 372 7101
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
The following information is intended for healthcare professionals only:
PRACTICAL INFORMATION FOR HEALTHCARE PROFESSIONALS
ON PREPARATION AND HANDLING OF ZALTRAP 25 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION
This information supplements the sections 3 and 5 for the user.
It is important that you read the entire content of this procedure prior to the preparation of infusion solution.
ZALTRAP is a sterile,
Caution should be exercised when handling ZALTRAP, taking into account the use of containment devices, personal protective equipment (e.g. gloves), and preparation procedures.
Preparation of the infusion solution
•Inspect the ZALTRAP vial visually prior to use. The concentrate solution must be clear and without particles.
•Based on the required dose for the patient, withdraw the necessary volume of ZALTRAP concentrate from the vial. More than one vial could be needed for the preparation of the infusion solution.
•Dilute it to the required administration volume with sodium chloride 9 mg/ml (0.9 %) solution or 5% glucose solution for infusion. The concentration of the final ZALTRAP solution for intravenous infusion should be kept within the range of 0.6 mg/ml to 8 mg/ml of aflibercept.
•PVC containing DEHP infusion bags or polyolefin infusion bags should be used.
•The diluted solution should be inspected visually for particulate matter and discolouration prior to administration. If any discolouration or particulate matter is observed, the reconstituted solution should be discarded.
•ZALTRAP is a
Chemical and physical
From a microbiological point of view, the solution for infusion should be used immediately.
If not used immediately,
Method of administration
ZALTRAP is to be administered only as an intravenous infusion over 1 hour. Due to hyperosmolality (1000 mOsmol/kg) of the ZALTRAP concentrate, undiluted ZALTRAP concentrate must not be administered as an intravenous push or bolus. ZALTRAP must not be administered as an intravitreal injection (see section 2 of the package leaflet).
Each vial of concentrate for solution for infusion is for single use
Diluted solutions of ZALTRAP should be administered using infusion sets containing a 0.2 micron polyethersulfone filter.
The infusion sets should be made of one of the following materials:
•polyvinyl chloride (PVC) containing
•DEHP free PVC containing
•polyethylene lined PVC
Filters made of polyvinylidene fluoride (PVDF) or nylon must not be used.
Any unused medicine or waste material should be disposed of in accordance with local requirements.